You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
CEFTAZIDIME JUNO is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. Indications include: Severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. Respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. Severe ear, nose and throat infections: for example: otitis media, mastoiditis. Urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. Skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. Gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. Bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.
White or cream coloured powder supplied in 50 mL capacity colourless, Type III glass vials, and sealed with Helvoet Pharma FM257/2 dark grey bromobutyl rubber stopper and dark green aluminium flip-off cap.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
CEFTAZIDIME JUNO is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. Indications include: Severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. Respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. Severe ear, nose and throat infections: for example: otitis media, mastoiditis. Urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. Skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. Gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. Bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.
White or cream coloured powder supplied in 10 mL capacity colourless, Type III glass vials, and sealed with Helvoet Pharma FM257/2 dark grey bromobutyl rubber stopper and violet aluminium flip-off cap.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
CEFTAZIDIME JUNO is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. Indications include: Severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. Respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. Severe ear, nose and throat infections: for example: otitis media, mastoiditis. Urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. Skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. Gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. Bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.
White or cream coloured powder supplied in 10 mL capacity colourless, Type III glass vials, and sealed with Helvoet Pharma FM257/2 dark grey bromobutyl rubber stopper and violet aluminium flip-off cap.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
CEFTAZIDIME JUNO is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. Indications include: Severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. Respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. Severe ear, nose and throat infections: for example: otitis media, mastoiditis. Urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. Skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. Gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. Bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.
White or cream coloured powder supplied in 10 mL capacity colourless, Type III glass vials, and sealed with Helvoet Pharma FM257/2 dark grey bromobutyl rubber stopper and violet aluminium flip-off cap.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.